Aura Biosciences, Inc. Stock Price, News & Analysis

Aura Biosciences (NASDAQ: AURA) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company now expects to complete enrollment in its global Phase 3 CoMpass trial in 2026 with topline data for the 15-month primary endpoint in Q4 2027. The Phase 1b/2 NMIBC trial remains on track with initial three-month data expected in mid-2026. Phase 1 immune-profiling showed de novo mature tertiary lymphoid structures in 3/5 patients and increases in NK and T-cell densities (NK up to 40x, CD4+ cytolytic up to 7x).

Financials: cash and marketable securities of $161.9M as of Sept 30, 2025, funding operations into the first half of 2027. R&D expense rose to $22.2M (Q3 2025) and net loss was $26.1M for the quarter.

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

The company's CEO, Elisabet de los Pinos, PhD, will deliver a presentation on September 10, 2025, at 11:00 a.m. ET. Investors can access the live webcast through Aura's investor relations website, where it will remain available for replay for 90 days after the presentation.

Aura Biosciences (NASDAQ: AURA) reported Q2 2025 financial results and clinical progress updates. The company strengthened its financial position with a $75 million equity financing, extending cash runway into H1 2027. Current cash position stands at $177.3 million.

Key clinical developments include the ongoing global Phase 3 CoMpass trial in early choroidal melanoma, with over 240 patients registered for pre-screening and expected completion by end of 2025. The company is also advancing a Phase 1b/2 trial in non-muscle invasive bladder cancer (NMIBC) and expanding its ocular oncology program to include metastases to the choroid and cancers of the ocular surface.

Q2 2025 financials showed increased R&D expenses of $22.9 million (vs $16.9M in Q2 2024) and slightly decreased G&A expenses of $5.7 million (vs $5.9M in Q2 2024). Net loss widened to $27.0 million compared to $20.3 million in Q2 2024.

Aura Biosciences (NASDAQ: AURA) has announced the pricing of a public offering expected to raise $75.0 million in gross proceeds. The offering consists of:

- 11,735,565 shares of common stock with warrants to purchase 2,933,891 additional shares

- Pre-funded warrants to purchase 3,571,435 shares (exercise price: $0.00001) with warrants to purchase 892,858 additional shares

The combined offering price is $4.90 per share of common stock and accompanying warrant, while pre-funded warrants are priced at $4.89999. The accompanying warrants have a 5-year term with a $4.90 exercise price. Proceeds will fund clinical programs in early-stage choroidal melanoma, metastases to the choroid, ocular surface cancers, and non-muscle invasive bladder cancer.

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on precision therapies for solid tumors, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock, warrants to purchase common stock, and pre-funded warrants with accompanying common stock warrants.

The offering will be managed by Leerink Partners and Evercore ISI as joint bookrunning managers, with LifeSci Capital as an additional bookrunning manager. Citizens Capital Markets and Scotiabank are serving as co-managers. The offering will be conducted under a shelf registration statement that was declared effective by the SEC on April 5, 2024.

Aura Biosciences (NASDAQ: AURA) reported Q1 2025 financial results and key developments. The company's lead candidate bel-sar is advancing in multiple clinical trials. The global Phase 3 CoMpass trial for early-stage choroidal melanoma has registered over 220 patients for pre-screening, with potential enrollment completion by end of 2025. The company also enrolled its first patient in a Phase 1b/2 trial for non-muscle-invasive bladder cancer (NMIBC), with initial data expected by year-end 2025.

Financial highlights include cash position of $128.0 million, expected to fund operations into H2 2026. Q1 2025 saw increased R&D expenses of $23.3 million (vs $17.1M in Q1 2024) and net loss of $27.5 million (vs $19.7M in Q1 2024). The company strengthened its leadership by appointing Tony Gibney as CFO and Business Officer.

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in three upcoming investor conferences in May 2025:

• The Citizens Life Sciences Conference - Fireside Chat on May 8, 2025, at 9:30 a.m. ET
• H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - Fireside Chat on May 20, 2025, at 2:00 p.m. ET
• TD Cowen 6th Annual Oncology Innovation Summit - Fireside Chat on May 27, 2025, at 10:00 a.m. ET

Live webcasts will be available on the company's investor relations website, with replays accessible for 90 days after each presentation.

Aura Biosciences (NASDAQ: AURA) has appointed Teresa Bitetti to its Board of Directors, effective March 31, 2025. Bitetti currently serves as President of the Global Oncology Business Unit at Takeda, where she manages a multi-billion-dollar oncology portfolio across major markets including the US, Europe, and Japan.

As a seasoned executive, Bitetti brings extensive operational and commercial experience from her previous roles, including Senior Vice President positions at Bristol Myers Squibb (BMS) where she led worldwide oncology commercialization and headed U.S. Oncology operations. Her expertise spans multiple therapeutic areas including infectious diseases and neuroscience.

The appointment aligns with Aura's focus on developing precision therapies for solid tumors while preserving organ function, particularly in ocular and urologic oncology.

Aura Biosciences (NASDAQ: AURA) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical pipeline. The company's lead candidate bel-sar showed positive Phase 1 trial data in Non-Muscle Invasive Bladder Cancer (NMIBC) at the European Association of Urology Congress, demonstrating clinical complete responses and robust cell-mediated immunity.

The Phase 3 CoMpass trial for early-stage choroidal melanoma is actively enrolling globally, with over 175 patients registered in pre-screening since June 2024. The company has also initiated a Phase 2 trial for metastases to the choroid, with initial data expected in 2025.

Financial highlights include:

• Cash position of $151.1 million, expected to fund operations into 2H 2026
• R&D expenses increased to $73.3 million for full year 2024
• Net loss of $86.9 million for full year 2024